The firm stated it has acquired approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes sufferers with power kidney illness (CKD).

Dapagliflozin is the primary and solely anti-diabetic drug accredited to considerably cut back the danger of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations as a result of coronary heart failure in adults with progressive power kidney illness, the drug agency stated.

The approval is relevant for each diabetic and non-diabetic CKD sufferers, it added.

CKD is among the main causes of hospitalisation globally and in India, representing a big scientific and financial burden.

“The timely approval of Dapagliflozin from the CDCSCO committee with the additional indication is a huge boost for nephrologists across the country towards the management of progressive CKD,” AstraZeneca India Vice President – Medical Affairs and Regulatory Anil Kukreja stated in a press release.

The approval will present the scientific neighborhood with a possible therapeutic choice to arrest the development of CKDs and handle coronary heart failures at an early stage, he added.